📅 26 August 2026🏷 Fillers and Injectables

SKINVIVE by Juvederm: What It Is, and What the FDA Data Shows

By Lucas, Founder & Lead Researcher

Reviewed for medical accuracy against our Medical Review Board · Last updated 26 August 2026

Part of Dermal Fillers: The Complete Guide

SKINVIVE by Juvederm is a hyaluronic acid injectable at 12 mg/mL, placed in tiny amounts within the skin rather than underneath it. It is not a filler in the usual sense: it is not meant to add volume or lift anything. The FDA approved it for cheek skin smoothness in May 2023, and in June 2026 it added a second approval for neck lines.

Almost everything written about this product comes from the brand or from clinic marketing. What follows is taken from the two FDA Summary of Safety and Effectiveness Data documents behind the two approvals, which contain the trial numbers, the control arms and the side effect durations. Those are the parts that answer whether it is worth your money.

1. What it actually is

From the FDA device description: a sterile, biodegradable, non-pyrogenic, viscoelastic, clear colourless gel of hyaluronic acid produced by Streptococcus species at a concentration of 12 mg/mL, crosslinked with BDDE, containing 0.3% lidocaine. A retail box holds two prefilled 1.0 mL syringes and comes with 32 gauge half-inch needles.

Two details in that paragraph matter more than anything in the marketing.

12 mg/mL is a low concentration on purpose. Volumising hyaluronic acid fillers are formulated to hold their shape and push tissue outwards. This is formulated to sit inside the dermis and hydrate it. That is why the approved wording is "improve skin smoothness" rather than augment, lift or correct. If a clinic offers it to you for volume loss, they are describing a different product.

The needle is also telling. A 32 gauge half-inch needle is very fine and very short, because the product is deposited in small amounts within the skin rather than in the deeper planes where the rest of the Juvederm range is placed.

2. Why it is not really a filler, and not Botox

What each of the three does, and what it is approved to do. Filler and toxin figures are from their own FDA labelling.
	SKINVIVE	Volumising HA filler	Botox
What it is	HA at 12 mg/mL	HA, higher concentration and crosslinking	Botulinum toxin type A
Where it goes	Intradermal, within the skin	Subcutaneous or deeper	Into muscle
What it does	Improves skin smoothness	Adds volume, lifts	Relaxes muscle
Does it stop movement	No	No	Yes, that is the mechanism
Does it add volume	No	Yes	No

So it does not compete with either. It is closer in intent to a skin quality treatment than to either injectable, which is why it is often discussed alongside them rather than instead of them. Our guide on Botox versus fillers covers that distinction in general, and the dermal fillers guide covers the volumising products properly.

3. The two approvals

Both approvals are panel-track supplements to the original Juvederm Voluma XC application P110033, which the FDA approved on 22 October 2013.
Approval	Date	Indication, as written
P110033/S059	11 May 2023	Intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21
P110033/S099	11 June 2026	Intradermal and/or subdermal injection to reduce neck lines for improvement of neck appearance in adults over the age of 21

The second one is ten weeks old at the time of writing and is the reason this product is being talked about again. It also added a specific cannula, the TSK 25 gauge one-and-a-half inch STERiGLIDE, for use with a needle in neck treatment. The neck trial and what it found has its own page, because the numbers are different from the cheek ones and the treatment is not the same procedure.

Note the age wording in both: adults over the age of 21. That is the labelled population, and it is worth knowing given how much of this product's marketing runs on social media.

4. What the cheek trial found

The 2023 approval rested on a randomised study measured on the Allergan Cheek Smoothness Scale. The FDA summary reports the month 1 results split by Fitzpatrick skin phototype, which is unusual to see published and useful if you have been told a treatment "has not been studied in skin like yours":

Proportion achieving at least a 1-point improvement on the Allergan Cheek Smoothness Scale at month 1, by Fitzpatrick phototype. From the P110033/S059 FDA summary.
Fitzpatrick type	SKINVIVE	Control
I	40.0% (2/5)	not available
II	57.6% (19/33)	14.3% (2/14)
III	59.2% (29/49)	6.3% (1/16)
IV	65.2% (15/23)	0% (0/13)
V	44.4% (4/9)	0% (0/5)
VI	66.7% (4/6)	33.3% (1/3)

Read the group sizes as well as the percentages. Types I, V and VI had five, nine and six participants, so those percentages rest on two, four and four people respectively and should be treated as indicative rather than precise. Types II, III and IV, where most participants sat, land between 57.6% and 65.2%, against control arms of 0% to 14.3%.

5. What the 2026 neck trial found

The headline from the pivotal neck study: at one month, 74.8% of the treatment group were rated improved by a blinded evaluator, against 16.1% of a no-treatment control group. That is a 58.7 point difference and it was highly statistically significant.

Two things about that pair of numbers. The 16.1% is the honest reference point, because roughly one person in six was rated improved having had nothing done at all. And the control arm here received no treatment rather than a sham injection, so it does not account for the effect of simply having had a procedure. Both figures, the study design and the durability data out to six months are set out on the neck lines page.

6. Side effects, and how long they last

This is where the FDA documents earn their keep, because the number that matters is not in any marketing material.

In the neck study, 89.8% of treated participants reported an injection site reaction. Of 147 who kept a 30 day diary, 132 had one. 42.9% were mild, 42.2% were moderate, which the diary defined as uncomfortable, and 4.8% were severe. On duration: 22.4% resolved in four to seven days, 24.5% in eight to fourteen, 29.3% lasted fifteen to thirty days, and 7.5% lasted longer than thirty days.

So this is not reliably a lunchtime treatment with an evening out afterwards. Nearly a third of people in the trial had something visible or uncomfortable for two to four weeks. The reactions themselves are the ordinary list for any injectable: redness, bruising, tenderness, lumps and bumps, swelling, firmness, pain, discoloration and itching.

Separately from those injection site reactions, treatment-related adverse events were uncommon: five of the 148 treated participants had one. That distinction matters. Injection site reactions were close to universal and mostly self-limiting; adverse events proper were rare.

Anything involving a needle and a gel implant carries the small but serious risks common to all fillers, including vascular occlusion. Those are covered on the filler complications page, and they are a reason to care who is holding the syringe. Our guide to verifying an injector's licence covers how to check.

7. Who it suits, and who it does not

It suits someone whose complaint is skin texture and dullness on the cheeks, or fine transverse neck lines, who understands they are buying skin quality rather than shape.
It does not suit volume loss, sagging, jawline definition or deep folds. Those are different products and different planes, and no amount of a 12 mg/mL gel placed in the dermis will address them.
It does not replace toxin. Neck lines that appear when you tense are muscle bands, which is a different problem with a different treatment, covered on the platysmal bands page. Static horizontal neck lines are what this approval addresses.
Under 21 is off label. Both indications specify adults over 21.

8. What to ask before you book

Which indication am I being treated for? Cheeks and neck are separate approvals with separate techniques. There is no approved indication for anywhere else, so anything beyond those two is off label and you should be told so.
How many syringes, and what is the total? The box contains two 1.0 mL syringes. Ask what a session actually uses.
What is the realistic downtime? If the answer is "none", show them the duration figures above. Almost a third of trial participants had a reaction lasting two to four weeks.
What happens at one month? The trials both allowed an optional touch-up at day 30, and the reported results are "after initial or optional touch-up". Ask whether a touch-up is included in the price you are quoted or charged again.
How long before I need it again? In the neck study 66.0% still met the improvement threshold at six months. That is the number to plan around, not twelve months.

Frequently asked questions

What is SKINVIVE by Juvederm?

A hyaluronic acid injectable gel at 12 mg/mL with 0.3% lidocaine, placed within the skin rather than beneath it. The FDA approved it in May 2023 to improve skin smoothness of the cheeks, and in June 2026 added an indication to reduce neck lines. Both are for adults over 21.

Is SKINVIVE a filler?

Technically it is a dermal filler and the FDA classifies it as one, but it does not do what people usually mean by filler. At 12 mg/mL it is far less concentrated than a volumising HA product and it goes into the dermis rather than the deeper planes. The approved wording is to improve skin smoothness, not to add volume or lift.

Is SKINVIVE the same as Botox?

No, and they are not alternatives to each other. Botox is a botulinum toxin that relaxes muscle. SKINVIVE is hyaluronic acid that hydrates skin. It has no effect on movement and Botox has no effect on skin texture.

How long does SKINVIVE last?

In the pivotal neck study, 66.0% of treated participants still met the improvement threshold at six months after initial or touch-up treatment, on a blinded evaluator's assessment. Responder rates were 76.8% at month 1, 78.0% at month 2 and 75.0% at month 4, so six months is the sensible planning horizon rather than a year.

What are the side effects of SKINVIVE?

Injection site reactions are close to universal. In the neck trial 89.8% of participants reported one: 42.9% mild, 42.2% moderate and 4.8% severe. On duration, 29.3% lasted 15 to 30 days and 7.5% beyond 30 days. Separately, treatment-related adverse events proper were uncommon, occurring in 5 of 148 treated participants.

Is there really no downtime with SKINVIVE?

That claim does not survive the trial data. Nearly a third of participants in the neck study had an injection site reaction lasting two to four weeks, and 42.2% of reactions were rated moderate, meaning uncomfortable. Most are mild and short, but planning on zero downtime is optimistic.

Can SKINVIVE be used on the neck?

Yes, since 11 June 2026. The FDA approved a second indication for intradermal and/or subdermal injection to reduce neck lines in adults over 21, alongside a specific cannula for the procedure. Before that date, neck use was off label.

Does SKINVIVE work on darker skin?

The cheek trial reported month 1 results by Fitzpatrick phototype, which most trials do not publish. Improvement rates were 57.6% for type II, 59.2% for III, 65.2% for IV, 44.4% for V and 66.7% for VI, against control arms of 0% to 33.3%. The type V and VI groups were only nine and six participants, so read those as indicative.

Written by

Lucas Pradella

Founder & Lead Researcher, BestBotoxClinics.com

Lucas founded BestBotoxClinics.com to bring clarity to the aesthetics industry, bringing 13+ years of experience in digital research and analysing online data for signals of quality and trust. He is not a physician, his work is research, data analysis and verifying provider credentials.

More about Lucas · How we work

Medical accuracy: BestBotoxClinics.com maintains a Medical Review Board of licensed clinicians. This article is educational and is not medical advice.